An Open-Label, Dose-Escalation Study of AZD2461
Study identifier:D3660C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients with Refractory Solid Tumors
Medical condition
Refractory solid tumors
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2461
Sex
All
Actual Enrollment
75
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Nov 2010
Primary Completion Date: 01 May 2011
Study Completion Date: 01 May 2011
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD2461 oral capsules, continuous dosing and intermittent dosing |
Contacts
Investigators
Principal Investigator
Andrew Hughes
AstraZeneca
